Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

Arrowhead (ARWR) announced presentation of preclinical data supporting the advancement of two clinical stage, RNAi-based investigational ...

Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase ...

Gestational diabetes is a common condition in which a person’s blood glucose (sugar) increases during pregnancy. While there are factors that can increase the risk of gestational diabetes—like having ...

All animal experiments were performed after receiving consent from Southern Medical University’s ethics review committee for animal experimentation. Cellular Assay of HBV Inhibition by siRNA The siRNA ...

Junevity Inc. has raised $10 million in seed funding to support its work creating silencing RNA (siRNA) therapeutics to address metabolic and age-related diseases, including type 2 diabetes, obesity ...

Intermittent fasting may benefit people with type 2 diabetes. Many people believe that intermittent fasting can aid weight loss and offer other health benefits. This article examines whether this ...

In Type 2 diabetes, Junevity’s first siRNA therapeutic candidate improved glucose control and insulin sensitivity in diabetic mice without causing weight gain or other side effects associated ...

02/13/2025 February 13, 2025 Can breathing toxic air increase our risk of diabetes? Plus: The food forest in Tamil Nadu growing planet-friendly, healthy food, and the move to empower women working ...

“It uses a unique technique called small interfering RNA (siRNA) to silence the PCSK9 gene, which results in more consistent, long-term reduction in LDL. Additionally, Inclisran’s mechanism of action ...

Hepatocyte cell death and liver regeneration in mice treated with the Fah-siRNA. (A to C) Representative H&E (A), TUNEL (B) and Ki67 (C) staining in livers from Control, Unselected, and Repair ...